NITAG recommendations

5 February 2024

02/05/2024 CTAI-HPV subgroup HPV VACCINATION MEETING IN PREPARED PERSONS: PROTOCOL AND IMPLEMENTATION  

Taking into account the morbidity profile of PrEP users (with increased vulnerability to sexually transmitted infections), as well as the efficacy of the vaccine in reducing lesions related to HPV genotypes, it was unanimously recommended to extend HPV vaccination to PrEP users aged 15-45 years, according to the guidelines below:  

NOT vaccinated against HPV: Administer 3 (two) doses: 0 - 2 - 6 months (Second dose two months after the first and third dose 6 months after the first dose).  

HPV vaccine is contraindicated for pregnant women, who should wait until after the puerperium to be vaccinated. In addition, the HPV vaccine is also contraindicated for anyone allergic to any of the components of this immunobiologic.  

Note: Persons on PrEP who have already been vaccinated with the full schedule recommended for certain age groups or special situations should not be vaccinated again with any dose. In the case of persons on PrEP who have been previously vaccinated, but with an incomplete schedule, they should complete all three doses.  

PrEP users can be vaccinated against HPV at any public vaccination center (Vaccination Posts, CRIE, Specialized Care Service/SAE, Testing and Counseling Center, as long as they present any kind of proof that they are taking PrEP (medical prescription or from already defined PrEP prescribers, follow-up card, medication, etc).  

Specific access requirements can be agreed upon at the local (Bipartite) level.  

Country
Brazil

Keywords